Overview

A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The aim of this study was to determine whether long-term (≥ 6 months at the target dose) blockade of ETA receptors using sitaxsentan showed functional benefit in subjects with chronic Heart Failure and an Left Ventricular Ejection Fraction ≥50%.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Sitaxsentan